The FDA has approved Trumenba (Pfizer), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, for use in adolescents and young adults 10-25 years old.

SEROGROUP B MENINGOCOCCAL VACCINES — Until recently, no serogroup B meningococcal vaccine was available in the US because the polysaccharide capsule of the B serogroup is only weakly immunogenic. A different meningococcal B vaccine (4CMenB; Bexsero) has been approved for use in Canada, the European Union, and Australia. In late 2013 and early 2014, the FDA and the CDC permitted the importation and investigational use of Bexsero in two outbreaks of serogroup B meningococcal disease.1

MENINGOCOCCAL DISEASE — Five major serogroups (A, B, C, Y, and W-135) of N. meningitidis cause most invasive meningococcal ... more      

Would you like to read the rest of this article?  Gain access below.